GlaxoSmithKline has no plans to delist Indian arm - exec
MUMBAI (Reuters) - GlaxoSmithKline Plc (GSK.L) has no plans to delist its Indian consumer products arm GlaxoSmithKline Consumer Healthcare Ltd (GLSM.NS), David Redfern, chief strategy officer at Britain's biggest drugmaker, said on Monday.
GSK said earlier it planned to buy up to an additional 31.8 percent stake in the Indian unit for 52.2 billion rupees.
The company has been expanding into both emerging markets and non-prescription consumer health - and in some cases a combination of the two.
The company, which plans to launch new variants of the flagship Horlicks brand in India, is looking to increase penetration of the product in the north and western regions of the country, Redfern said. (Reporting by Kaustubh Kulkarni; Editing by Subhranshu Sahu)
- Tweet this
- Share this
- Digg this
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- INSIGHT - As Islamic State fighters begin to blend in, defeating them no easy matter
- RBI rule handicaps India's infrastructure hopes
- Japan aims to double India investment in 5 years - Nikkei
- Family of seriously ill Joan Rivers 'keeping fingers crossed' -daughter
The Nifty surged past the psychologically important 8,000 level for the first time to mark its latest record high as blue-chips such as Larsen & Toubro gained after better than expected quarterly economic growth data. Read